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Defining optimal routes for induction of mucosal immunity represents an important research
priority for the HIV-1 vaccine field. In particular, it remains unclear whether mucosal routes
of immunization can improve mucosal immune responses.
Methods
In this randomized two center phase I clinical trial we evaluated the systemic and mucosal
immune response to a candidate HIV-1 Clade C CN54gp140 envelope glycoprotein vaccine
administered by intramuscular (IM), intranasal (IN) and intravaginal (IVAG) routes of admin-
istration in HIV negative female volunteers. IM immunizations were co-administered with
Glucopyranosyl Lipid Adjuvant (GLA), IN immunizations with 0.5% chitosan and IVAG
immunizations were administered in an aqueous gel.
Results
Three IM immunizations of CN54 gp140 at either 20 or 100 μg elicited significantly greater
systemic and mucosal antibodies than either IN or IVAG immunizations. Following
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additional intramuscular boosting we observed an anamnestic antibody response in nasally
primed subjects. Modest neutralizing responses were detected against closely matched tier
1 clade C virus in the IM groups. Interestingly, the strongest CD4 T-cell responses were
detected after IN and not IM immunization.
Conclusions
These data show that parenteral immunization elicits systemic and mucosal antibodies in
women. Interestingly IN immunization was an effective prime for IM boost, while IVAG
administration had no detectable impact on systemic or mucosal responses despite IM
priming.
Clinical Trials Registration
EudraCT 2010-019103-27 and the UK Clinical Research Network (UKCRN) Number 11679
Introduction
The need for a vaccine capable of reducing heterosexual transmission of HIV-1 via the female
genital tract remains an urgent priority for curbing the epidemic in women. A key attribute of
such a vaccine will be its ability to induce protective antibodies in the vagina and cervix that
could prevent transmission of HIV to women of child-bearing age, without compromising fer-
tility. This approach is supported by non-human primate (NHP) studies demonstrating that
neutralizing antibodies can prevent vaginal acquisition when administered by intravenous
infusion or applied topically to the vagina [1–4]. However, the relative importance of antibody
levels in secretions versus mucosal tissue and the role of non-neutralizing antibodies in vaginal
acquisition has yet to be fully defined [1,5]. The modest reduction in risk of HIV acquisition in
the human RV144 “Thai” efficacy trial is thought to correlate with polyclonal non-neutralizing
antibodies against the V1V2 region of gp120, in particular the IgG1 and IgG3 subclass, associ-
ated with antibody dependent cytotoxicity (ADCC). Interestingly, high systemic levels of enve-
lope (Env) specific IgA targeting the same epitopes were directly correlated with risk, although
mucosal levels of specific IgG and IgA were not determined [6, 7].
Different strategies for optimal induction of vaginal antibody responses have been explored
in a number of animal models. These studies led to the concept of immunological linkage
between the upper respiratory tract and lower genital tract [8]. For example, preclinical studies
of intranasal (IN) immunization of mice with HIV gp140 were shown to elicit specific antibod-
ies in vaginal secretions [9, 10]. Nasal immunization with CTB has been associated with vaginal
antibodies in humans and induced stronger responses than those seen with direct IVAG
immunization [11], although no comparison was made to parenteral vaccination. Currently
the only examples of vaccine-induced protection against cervico-vaginal viral infection are the
two licensed parenteral vaccines against human papillomaviruses [12]. These responses are
assumed to be due to transudation of neutralizing IgG from the plasma into cervico-vaginal tis-
sue and/or secretions [13, 14]. There has only been one previous clinical study of parenteral
vaccination with recombinant gp140 alone (in the absence of DNA or viral vector priming),
this included limited immunological analysis and did not assess vaginal antibody levels [15].
Data on the effects of direct vaginal vaccination in humans are extremely limited. In preclinical
studies direct vaginal administration of gp140 in mice fails to induce local and systemic anti-
body responses, whilst in NHP this approach is partially effective and in rabbits it appears to be
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highly effective [9, 16, 17]. However, clinical studies of direct vaginal vaccination with gp140 in
the absence of a parenteral prime have thus far failed to induce mucosal antibody responses
[18, 19].
To the best of our knowledge this is the first comparative Phase I clinical trial in women to
investigate the safety and immunogenicity of three HIV-1 clade C gp140 immunizations deliv-
ered by intramuscular (IM), intranasal (IN) and intravaginal (IVAG) routes with a specific
focus on antibody responses to gp140 in cervico-vaginal secretions and in serum. The choice of
a clade C immunogen was based on the high global prevalence of this HIV-1 subtype and in
particular for its relevance to sub-Saharan Africa.
Methods
Vaccines
The recombinant clade C HIV-1 envelope gp140 protein (CN54gp140) is a naturally cleavage
resistant, envelope clone of 97CN54 [20]. Recombinant CN54gp140 was manufactured to
GMP specification [21] (Polymun Scientific, Austria) providing a product that was>80% tri-
meric, with a projected mass of 420 kD and a defined glycan profile [20]. For IM immuniza-
tions either 20 (IM20) or 100 μg (IM100) CN54gp140 was mixed with 5 μg Glucopyranosyl
Lipid Adjuvant- aqueous formulation (GLA-AF) (IDRI, Seattle USA) [22] and administered in
0.4mls into the deltoid muscle. For IN immunization, 100 μg CN54gp140 was mixed with 0.5%
(w/v) chitosan in 0.2ml (NovaMatrix, Norway) and dropped into each anterior nares [23]. For
each IVAG immunization 500 μg CN54gp140 was given in a 1m aqueous gel vehicle (Particle
Sciences Inc., USA) administered using an applicator directly into the vagina [19].
Study design and conduct
Mucovac2 was a Phase I randomized trial conducted at two centers; (St Georges University of
London (SGUL) and Hull York Medical School, Experimental Medicines Unit (HYMS EMU).
Volunteers were enrolled 17th November 2011 to 7th August 2012, follow-up for the study was
completed on 11th January 2013. All participants gave fully informed written consent and all
relevant approvals were in place, the trial being conducted according to the UK Clinical Trials
Regulations and GCP guidelines; reviewed and approved by NRES London Bridge Research
Ethics Committee (S1 CONSORT Checklist). The trial was registered with the UK Clinical
Research Network (UKCRN) assigned No. 11679 and the European Union Drug Regulating
Authorities for Clinical Trials and assigned the EudraTC No. 2010-019103-27. The primary
objective was to determine the safety and immunogenicity of the vaccination regimes in
healthy female volunteers aged 18–45 years who were at low risk for HIV infection. The trial
was open-label with laboratory assessment staff blind to regimen throughout and the partici-
pants blind to the dose administered in the intramuscular regimen. Eligible female participants
were randomised centrally into one of the four groups using a computer-generated algorithm
based on random permuted blocks stratified over one factor (clinical centres) aiming to enroll
10 individuals into each of the IM20, IM100 and IVAG groups and 6 into the IN group (as
there were no responses following IN immunization in a preceding macaque experiment; at
SGUL), 36 in total (Fig 1). Statistical Software Stata (StataCorp. 2011. Release 12. College Sta-
tion, TX) was used by the trial statistician to create the randomization sequence with variable
block sizes (3 and 6 for HYMS; 4, 8 and 12 for SGUL). Women in the IVAG group received a
single IM prime (100ug) followed by two IVAG immunizations. Volunteers from the IM100
and IN groups were invited back to receive two further boosts of 100 μg gp140 adjuvanted with
GLA-AF IM 4 weeks apart within 12–24 weeks of the last vaccination (full details in S1 Study
Protocol).
Immunogenicity of HIV-1 CN54gp140
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Fig 1. CONSORT Flow diagram.Numbers of participants recruited into the trial “Analysis 1”is the original protocol schedule
to week 20 incorporating the planned main analysis. Five from IM100 and 3 from the IN group also received additional boost
vaccinations following an amendment to the protocol, and these individuals were included in the exploratory “Boost Analysis
-2”.
doi:10.1371/journal.pone.0152038.g001
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Safety, reactogenicity and adverse events evaluation
Information on adverse events was collected at every visit. Information on solicited adverse
events was collected one hour post-immunization, one week later, and recorded in diary cards
by the participants in the seven days following each immunization. The primary safety out-
come was a severe or worse local or systemic adverse event or an event that led to discontinua-
tion of the vaccine schedule.
Clinical specimens
Serum, PBMC and mucosal samples were collected for immunogenicity at baseline, and weeks
4, 5, 8, 12, 16 and 20. Genital tract secretions were collected using the Instead Softcup™ (Evofem
Inc) or Weck-Cel1 surgical spears (Medtronic). Weck-Cel samples were also taken from the
cervical os and vaginal fornices from all volunteers at screening and weeks 5 and 12. Mucosal
secretion samples were acquired and processed as detailed in S1 Text.
Assays of humoral immune responses
Serum and mucosal binding antibodies against recombinant CN54gp140 were measured using
a standardized ELISA with minor modifications as described in the S1 Text. Serum specificity
mapping was performed using a peptide epitope array of heterologous strains as previously
described [24]. Neutralizing titers were measured in TZM-bl and ADCC activity was assessed
as described [25, 26].
Assays of cellular immune response
Intracellular cytokine staining (ICS) was performed as described previously [27]. Vaccine-
induced T cell responses were analyzed using the mixture models for single-cell assays
(MIMOSA) [28] statistical analysis to delineate vaccine-specific T-cell induced profiles. Multi-
plex bead array (MBA) to measure cytokine profiles of responding cells was conducted as pre-
viously described [29].
Statistical analysis
Categorical variables were described by number, percentage and, where indicated, their 95%
confidence interval (Wilson CI suitable for small sample sizes). Comparisons of categorical
variables were made using Fisher’s exact test. The magnitude of an antibody response and
other continuous variables were compared between groups using non-parametric tests (Wil-
coxon matched-pairs signed rank test, or Mann-Whitney test). Association between continu-
ous variables was examined using rank correlation. The level of statistical significance was 5%
for all analyses, without adjustment for multiple comparisons. Statistical analyses were per-
formed using Stata (Version 12.1).
Results
Participant accrual, safety and reactogenicity
36 individuals were enrolled and randomized into four groups. As a result of differential enrol-
ment at the two sites, a small chance imbalance between the groups emerged with 11 partici-
pants allocated to IM20, 9 to IM100, 5 to IN, and 11 to IVAG groups. Additional boosting was
given to 5 participants in the IM100 group, and 3 in the IN group (Fig 1). Demographic charac-
teristics across randomization groups were balanced. There were no primary safety outcomes
during the trial. After 3 immunizations, all 36 participants had experienced at least one mild or
Immunogenicity of HIV-1 CN54gp140
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moderate solicited adverse event (Table 1). There were no significant differences in the median
number of events per participant (p = 0.27) or in the maximum grade between groups (p = 0.61).
Immunogenicity
CN54gp140-specific serum antibody responses. Systemic CN54gp140-specific IgG
responses were detectable one week after the second vaccination (Fig 2A) in the two IM groups.
The highest number of responders with a detectable serum IgG response across all groups (20/
36; 55%) was at Week 12, 4 weeks after the third immunization. 9/11 responded (detectable
IgG) in the IM20 group (median 5.32μg/ml; range 0.01–23.47 μg/ml) and 9/9 (median 4.18 μg/
ml; 1.23–12.01 μg/ml) in the IM100 group, with no significant difference between doses
(p = 0.71, Mann Whitney test). One individual in the IVAG group had a detectable serum IgG
response at Week 12 only and there were no detectable responses in the IN group. At Week 20,
6/11 (54.5%) and 6/9 (60%) still had detectable serum IgG in the IM20 and IM100 groups
respectively. Serum IgG antibody concentrations in responders from these two groups were
comparable throughout the vaccination schedule and during the follow-up period (Fig 3A).
There were no systemic vaccine-induced CN54gp140-specific IgA responses detected in any of
the samples from any of the participants during the trial.
CN54gp140-specific cervico-vaginal antibodies. CN54gp140-specific IgG antibodies
were detected in the cervico-vaginal secretions of eight individuals at Week 12 (Fig 2B and S1
Table). Of these, 4/11 (36%; 95% CI 15–65%) were in the IM20 group, and 4/9 (44%; 95% CI
19–73%) in the IM100 group. There were no responders in the IN or IVAG groups at Week 12.
Table 1. Summary safety data–adverse events during main trial¶.
IM 20 μg(n = 11) IM 100 μg (n = 9) Intranasal (n = 5) IM + IVAG (n = 11)
Primary Safety outcome: 0 0 0 0
SAEs: 2* 0 0 0
Total Solicited adverse events: 69 39 24 62
No. of events; Grade 1 63 37 24 60
No. of events: Grade 2 6 2 0 2
No. of subjects with any event 11 9 5 11
Median no. of events per subject 6 4 2 5
Max grade per subject: Grade 1 8 8 5 10
Max grade per subject: Grade 2 3 1 0 1
Total No. of subjects with local events 11 7 5 9
Injection-site 10 7 0 9
Nasal 1 0 5 1
Intravaginal 4 0 0 4
No. of subjects with systemic event 8 4 1 8
No. of subjects with lab event 2 5 3 6
Unsolicited adverse events
No. of events: 36 33 27 34
No. of subjects with any event 8 8 5 10
Median no. of events per subject 2 2 5 2
Table 1 footnotes:
¶ before boosting phase; there were no grade 3 or 4 solicited adverse events.
* Two serious adverse events were reported, the first was a suspected (accidental) paracetamol overdose, the second, a Bartholin abscess. Since this
individual was not in the IVAG group the cyst was considered unlikely vaccine related.
doi:10.1371/journal.pone.0152038.t001
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Responses were more reliably detected in Softcup samples than Weck-Cel (S1 Table). Across
all time-points, CN54gp140-specific IgG was detected in only 1/11 participants in the IVAG
group, and none of the participants in the IN group. At Week 20, 12 weeks after the third vacci-
nation, 2 individuals in the IM20 group, 3 in the IM100 group, and 1 in the IVAG group still
had detectable CN54gp140-specific IgG antibody (Fig 2B).
Fig 2. Participant response rates in systemic andmucosal compartments; Panel a) shows the numbers
of participants with a CN54gp140 IgG antibodies in serum according to vaccination group and timepoint from
randomisation. Panel b) shows the numbers of participants with CN54gp140 IgG antibodies in mucosal
samples by vaccination group. Filled bars show the number of participants with detectable CN54 IgG, open
bars show the number of participants with no CN54gp140 IgG antibodies.
doi:10.1371/journal.pone.0152038.g002
Immunogenicity of HIV-1 CN54gp140
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Fig 3. Magnitude of serumCN54gp140 IgG antibody responses for the two intramuscular vaccination
groups by timepoint from randomisation. Panel a) Serum CN54gp140 IgG levels measured by ELISA
expressed as μg/ml in either IM20 group (red circles) or IM100 group (black squares) at weeks 5, 8 12, 16
and 20. The black arrows indicate immunizations administered at weeks 0, 4 and 8 weeks. Panel b) Serum
IgG responses measured in the 8 participants that received boost immunizations at weeks 32 and 34 (shown
as arrows). Black symbols/lines indicate the 5 participants from the IM100 group, red symbols/lines indicate 3
participants from the IN prime group.
doi:10.1371/journal.pone.0152038.g003
Immunogenicity of HIV-1 CN54gp140
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Only 1/36 trial participants, an individual in the IVAG group, developed a cervico-vaginal
IgA response post vaccination, detected in the Softcup sample taken at Week 20 (0.157 μg/ml),
but not detectable at any other time-point. CN54gp140-specific IgG was also detected in the
Softcup sample at this time-point and at Week 8 in the absence of a serum IgG response. In
addition, two other participants had low but detectable IgA binding antibodies prior to
CN54gp140 vaccination thought to be polyreactive. In one of these, a response was also
detected at Weeks 2, 16, and 20. Total IgG and IgA were reliably and reproducibly detected in
softcup samples across all visits (S1A Fig), where the ratio of IgG:IgA was somewhere in
between cervical os and vaginal Weck-Cel samples (S1B and S1C Fig and S2 Table).
In the majority of participants, detection of specific IgG antibodies in cervico-vaginal secre-
tions corresponded with detection of specific IgG in serum (S2 Table). At Week 12, the 8 par-
ticipants with vaginal specific IgG (Softcup or Weck-Cel) had significantly higher serum IgG
titres than participants without detectable specific vaginal IgG (n = 8: median serum
CN54gp140 IgG 10.67μg [1.23–23.47μg/ml] versus n = 11 median 2.47μg/ml [0.01–20.96μg/
ml];p = 0.02 MannWhitney test). Detectable specific vaginal IgG (Softcup) was significantly
correlated with serum IgG titer (Spearman’s rank rs = 0.79, p = 0.036). At Week 16 and Week
20, median serum IgG titres were also greater in those with cervico-vaginal IgG, but this was
not significantly different. However, the systemic and mucosal levels were not necessarily cor-
related as there were individuals who had systemic responses of a similar magnitude in the
absence of any corresponding mucosal antibodies.
CN54gp140-specific IgG responses after additional boosting. Eight participants, 5 in
the IM100 and 3 in the IN group, received two further boosts delivered by IM immunization
with 100 μg of CN54gp140 adjuvanted with GLA-AF, 4 weeks apart, within 12–24 weeks of the
last vaccination. IM boosting elicited systemic IgG responses in all 3 participants in the IN
group, which were not previously apparent. These were detectable after the first IM vaccination
and were present at all 4 scheduled sampling time-points (Fig 3B). In addition, specific IgG
antibodies were also detected in the cervico-vaginal secretions from 1/3 participants, albeit
only at 2 Weeks post boost. Of the five subjects in the IM100 group who received the additional
two IM boosts, augmented IgG levels were observed after the first IM boost which although
sustained by the second boost did not show an apparent additional benefit (Fig 3B). 3/5 had
detectable cervico-vaginal specific IgG after the boost immunizations. Two of these individuals
had previously shown mucosal IgG antibodies during the main phase of the trial.
Serum peptide microarray analysis. The specificity of induced serum binding antibodies
was assessed by peptide microarray analysis. All responding subjects displayed predominant
responses to the V3 loop (Fig 4A and 4B). A subset of vaccinees also developed low levels of C5
or C1 gp120 Env IgG responses (Fig 4C). There was no significant binding to gp41 Env (data
not shown). The V3 gp120 IgG responses were focused on Clade C, with evidence of cross-
clade reactivity (mainly against Clade A, CRF02, and Group M). Among the 3 clade C peptide
sequences in the vaccine strain panel, the V3 response was targeted to 1086C and TV1
sequences. There was little correlation between the serum antibody titer and the number of epi-
topes recognized in the peptide array (Spearman’s correlation 0.42).
Neutralizing antibody activity and ADCC. Overall, neutralizing responses to tier 1
viruses were weak except for MW965.26 and TH023.6. Four weeks post third vaccination 7/11
individuals (87%) in the IM20 group, and 6/9 in the IM100 group (66.7%) showed responses
against MW965.26, with no responses in the IVAG or IN groups (Fig 5A–5D). For individuals
in the IN group that received additional IM boosting, response rate to MW965.26 increased
from 0 to 67% (2/3). The mean global binding antibody titer moderately correlated with the
neutralizing titer to MW965.26 (0.76, Spearman’s correlation), while binding intensity in the
V3 region by peptide microarray positively correlated with neutralization titer for TH023.6
Immunogenicity of HIV-1 CN54gp140
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Fig 4. Peptide binding array analysis against gp120 peptides in serum samples from participants that
developed a serumCN54gp140 IgG antibody response. Panel a) shows mean binding intensities against
Immunogenicity of HIV-1 CN54gp140
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(0.92, Spearman’s correlation) and weakly for MW965.26 (0.50). There was no detectable
ADCC activity in any of the samples exhibiting anti-Env antibodies four weeks after the third
gp140 vaccination (data not shown).
Cell-mediated immune responses. T-cell mediated immunity was assessed by intracellu-
lar cytokine staining (ICS). There were no detectable cytokine responses in the CD8 T-cell pop-
ulation in any group during the study (data not shown). Interestingly, modest responses to Env
were primarily observed in the CD4 cells from participants that received IN immunizations,
despite mounting no detectable antibody response. Responses were greatest in this cohort one
week post third immunization (Week 9), with 80% of individuals positive for CD154, 60% for
IL-2 and 60% for TNF-α expression (Fig 6A–6C). By contrast, responses were infrequent, and
of lower magnitude, in the IM20 parenteral group, and poorer still in the IM100 group. ICS
responsiveness was not significantly associated with IgG antibody titer or neutralizing titer.
Cytokine profiles were also measured by cytokine multiplex bead array (MBA) on supernatants
of stimulated PBMC with whole CN54gp140 or matched peptides. Again, responses were pre-
dominantly detected in participants that received IN immunizations with poor or no responses
detected in all other vaccination groups. In subjects where cells were available, the most consis-
tent responses to whole CN54gp140 in the IN group were seen in 75% of participants at Week
9 for IL-2, IL-5 and IL-13 (S2A–S2C Fig), with weaker and less frequent responses for GM-CSF
(2/4), IL-4 (2/4), IL-10 (2/4), and IL-17A (3/4 participants, data not depicted). Similar
responses were seen for the IN group when PBMC were stimulated with matched peptides
(two pools) in a Luminex assay. Here modest responses to most cytokines were seen in the IN
group at Weeks 9 and 12, specifically IL-2, IL-15 and TNF-β, with weak responses across the
other groups (S3A and S3B Fig).
Discussion
We conducted a novel randomized phase I trial of an HIV-1 Clade C gp140 envelope protein
comparing the safety and immunogenicity of IM immunization with two different mucosal
routes: IN and IVAG. All the participants completed their immunizations and there were no
severe adverse reactions reported (Table 1).
Serum CN54gp140 IgG responses were detected in the majority of participants in the two
parenteral groups. There was no statistical difference between the groups, suggesting the lower
dose of gp140 (20 μg) was similar to the standard dose (100 μg) when administered with adju-
vant. There were no detectable serum IgA responses. This may reflect the adjuvant properties
of GLA-AF. Given the potential negative correlation of specific systemic IgA in the RV144 trial
[6, 7] this may be a positive characteristic of the GLA formulation. Detectable specific vaginal
IgG (softcup) was significantly correlated with serum IgG titer, likely reflecting transfer of sys-
temic antibody into the vagina by passive transudation [13, 14]. It is likely that the frequency of
detectable vaginal antibody would be increased using strategies that elicit higher systemic
responses. However, the systemic and mucosal antibodies were not necessarily correlated as
there were some individuals who had systemic responses of a similar magnitude in the absence
of any specific mucosal IgG, suggesting factors in addition to serum titer may influence IgG
transfer to the vaginal lumen. The only previous clinical study of an HIV-1 subtype D gp140
envelope protein formulated in alum also showed antibody responses in all nine of the trial
participants. It is not possible to compare data between two studies as only very limited
consensus clades; Panel b) shows mean binding intensities against a variety of HIV-1 vaccine strains. Panel c)
Details the maximum binding intensities are shown according to participant at peak serum IgG response for the
two groups that received intramuscular immunizations.
doi:10.1371/journal.pone.0152038.g004
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immunological analysis of serum antibody response was reported using a clinical diagnostic
ELISA with no indication of serum dilutions. Mucosal and cellular responses were not
assessed [15].
Fig 5. Serum neutralizing antibody titres, analysed by TZM-bl assay. Data expressed as ID50 against a variety of viruses at (a) week 0,
b) week 12, c) week 20, and following additional boost in panel d).
doi:10.1371/journal.pone.0152038.g005
Immunogenicity of HIV-1 CN54gp140
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Serum IgG responses were highly focused on the immunodominant V3 loop. This is reflec-
tive of a number of gp140 immunogens recently evaluated in non-human primate models [30].
V3 dominated responses were mirrored by the low level of detectable neutralization to closely
matched tier 1 isolates. Binding intensity to the V3 region positively correlated to the neutrali-
zation of TH023.6 and only modestly with neutralization of MW965.26. Interestingly, as in
rabbits and macaques [16, 17], serum antibodies did not recognize the gp41-immunodominant
domain (residues 598–609) [31] and showed no significant binding to any part of gp41. This
suggests that the gp41 region of the molecule may be occluded from immune recognition,
potentially avoiding induction of diverting responses associated with gp41-cross reacting
microbiota [32]. The lack of any detectable ADCC activity likely reflects lack of response to
dominant epitopes associated with ADCC, typically V1/V2, C1 and gp41 [24, 33]. CN54 gp140
is naturally cleavage resistant constraining its ability to adopt a native-like conformation. It is
anticipated that next generation stabilized cleaved soluble trimers may provide significant
gains in neutralization breadth and potency [34].
Antibody responses to HIV-1 gp140 are thought to be dependent upon CD4 T- follicular
helper (Tfh) cells. The paucity of detectable systemic CD4 T-cell responses in the two IM groups,
despite robust antibody responses, suggests that required Tfh responses are likely restricted to the
germinal centers of localized lymph nodes, and/or do not circulate in sufficient numbers at sam-
pled time points (1 and 4 weeks post third immunization) to be detected. The observed paucity
in CD4 response following parenteral immunization is in marked contrast to the IN group where
80% of participants had detectable circulating CD4 T-cell responses as assessed by CD154
expression (CD40L, a marker of T cell activation) in the apparent absence of detectable serum or
vaginal antibody responses. It is unclear why we saw no effect of IN chitosan on humoral immu-
nity, given that previous clinical studies have shown that chitosan promoted potent antibody
responses to other immunogens [23, 35, 36], but it may be that these were intrinsically more anti-
genic. However, the induction of CD4 T-cell responses suggests effective uptake of CN54gp140
by local antigen presenting cells, and subsequent presentation to CD4+ helper T cells. These data
contrast with early preclinical studies from our group in mice, which suggested that chitosan
efficiently promoted both humoral systemic and mucosal responses to CN54gp140 [9, 37]. Inter-
estingly, all participants in the IN group that agreed to the boosting protocol immediately
responded to the first IM boost with serum antibody responses equivalent to those in the paren-
teral groups after three immunizations. Thus IN administration appeared to act as a mucosal
prime for subsequent systemic immunization. It is unclear whether priming was restricted to
induction of CD4 T cell help or included priming of antibody responses that were too low to be
detected. However the rapid anamnestic response on IM immunization is supportive of a boost-
ing of primed antibodies rather than de novo priming at inductive sites. The possible dependence
on potential adjuvant properties of chitosan cannot be inferred in the absence of a control arm. It
is likely that higher doses, and/or the inclusion of a more potent mucosal adjuvant, could provide
more positive immunogenicity data, even during the priming phase [38].
Vaginal CN54gp140-specific IgG antibody was detected in 36% and 44% of volunteers in
the parenteral IM20 and IM100 groups, and at low intermittent levels in one individual in the
IVAG group. There was no evidence for induction of specific IgA responses in any group,
Fig 6. T cell ICS analysis. The graphs display background corrected magnitude of T cell response for each
cytokine and T cell subset by visit as percentage staining shown as box plots. Here, cohort 1 = IM20, cohort
2 = IM100, cohort 3 = IN and cohort 4 = IVAG. Responders are colored red and non-responders blue.
Box plots based upon data from responders only are superimposed on the distributions, mid-line denotes
median,ends of the box denote 25th and 75th percentiles and where whiskers that extend from the top and
bottom are the extreme data points. Panel a) shows staining of CN54gp140 specific live CD3+/CD4+ CD154
+ cells, b) CD3+/CD4+ IL-2+, c) CD3+/CD4+ TNF-α+ according to vaccination group at weeks 0, 12 and 24.
doi:10.1371/journal.pone.0152038.g006
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including the IVAG group. We did however observe evidence of pre-existent, polyreactive
CN54gp140-binding IgA in two individuals prior to vaccination, as previously described [39]. The
lack of IVAG boosting following a single IM prime contrasts to our previous studies in macaques
where a single IM immunization primed animals for induced antibody following IVAG immuni-
zation [13]. However, animals received 9 IVAG immunizations (100 μg each) over one menstrual
cycle, as opposed to two higher doses (500 μg) used in this human study. Lack of responsiveness
following IVAG administration may reflect the absence of mucosal adjuvant, prompted by our
desire to minimize any local immune activation that might enhance HIV susceptibility [40]. How-
ever, in a different human study using CN54gp140 and HSP70 as an adjuvant, IVAG administra-
tion also failed to induce detectable systemic or mucosal antibody responses [18]. Furthermore, in
recent studies a wider range of adjuvants failed to induce vaginal antibodies in NHP [38].
In summary, this study comparing different routes of administration demonstrates that IM
administration of CN54gp140 elicited potent systemic IgG responses in the majority of sub-
jects, and detectable vaginal IgG in just over a third. The observation that the lower dose of
CN54gp140 (20 μg) was similar to the standard dose (100 μg) when formulated with GLA-AF
adjuvant, provides opportunities for dose sparing regimes. Interestingly, IN administration
induced detectable CD4 T cell responses and primed subsequent intramuscular boosting, while
IVAG administration in the absence of adjuvant had no detectable impact on systemic or
mucosal responses in spite of IM priming.
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